[A18-41] Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2018
Project no.:
A18-41
Commission:
Commission awarded on 21.06.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence, in combination with trastuzumab and chemotherapy
Patients < 65 years: added benefit not proven; patients ≥ 65 years: hint of lesser benefit in comparison with the appropriate comparator therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A13-28 | Addendum to Commission A13-10 (pertuzumab) | Commission completed |
| A16-01 | Pertuzumab - Addendum to Commission A15-34 | Commission completed |
| A13-10 | Pertuzumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A15-34 | Pertuzumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A18-76 | Pertuzumab (breast cancer) - Addendum to Commission A18-41 | Commission completed |
| A22-103 | Pertuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-102 | Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-12-20 A G-BA decision was published.